InMed Pharmaceuticals (INM) Net Cash Flow Growth (1y) (2020 - 2026)
InMed Pharmaceuticals (INM) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | -117.27% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -167.84% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -290.21% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 270.63% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -367.42% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | -7.60% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 272.00% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.64 Mn | 1.40 Mn | - | -216.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -216.11% |
| Dec 31, 2025 | -9.83% |
| Sep 30, 2025 | -76.50% |
| Jun 30, 2025 | 721.59% |
| Mar 31, 2025 | 165.16% |
| Dec 31, 2024 | -17.07% |
| Sep 30, 2024 | 54.53% |
| Jun 30, 2024 | -48.80% |
| Mar 31, 2024 | -4.64% |
| Dec 31, 2023 | -171.02% |
| Sep 30, 2023 | -168.51% |
| Jun 30, 2023 | -348.26% |
| Mar 31, 2023 | 65.65% |
| Dec 31, 2022 | 164.03% |
| Sep 30, 2022 | -60.23% |
| Jun 30, 2022 | 113.33% |
| Mar 31, 2022 | -849.58% |
| Dec 31, 2021 | -178.81% |
| Sep 30, 2021 | 655.67% |
| Jun 30, 2021 | -49.48% |